home / stock / orpof / orpof quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $4.00 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:41:07 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-24-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-23-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-22-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-21-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-20-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-17-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
OTCMKTS Market:
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage ...
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ Nantes, France – July 1 st , 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR...
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced that the Company has entered into a commercial ...